<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02313389</url>
  </required_header>
  <id_info>
    <org_study_id>P130950</org_study_id>
    <secondary_id>2014-002597-37</secondary_id>
    <nct_id>NCT02313389</nct_id>
  </id_info>
  <brief_title>Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma</brief_title>
  <acronym>BLOCAGE-01</acronym>
  <official_title>Phase III Trial Evaluating Maintenance Treatment Versus Observation in Elderly Patients Suffering From Primary Central Nervous System Lymphoma in Complete Remission After High Dose Methotrexate Based Chemotherapy in First Line</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis&#xD;
&#xD;
      Our hypothesis is that maintenance chemotherapy will prolong complete remission obtained&#xD;
      after a standard induction chemotherapy with an acceptable toxicity in the elderly.&#xD;
&#xD;
      Rationale&#xD;
&#xD;
        -  Treatment of the elderly is challenging, indeed age over 60 is associated both with a&#xD;
           poor prognosis and a high risk of treatment induced neurotoxicity with devastating&#xD;
           consequences on quality of life. Therefore it has become standard practice to treat&#xD;
           elderly in first line with high-dose methotrexate (MTX) based polychemotherapy alone,&#xD;
           avoiding whole brain radiotherapy (WBRT) or deferring it for recurrence.&#xD;
&#xD;
        -  There is a clear need to improve disease control after induction chemotherapy. Since&#xD;
           consolidation with WBRT or intensive chemotherapy with autologous stem cell rescue are&#xD;
           either poorly effective and/or too toxic in the elderly population, maintenance&#xD;
           chemotherapy is an interesting alternative approach. Several agents, such as high-dose&#xD;
           MTX, temozolomide (TMZ), rituximab, with a reported activity in PCNSL and acceptable&#xD;
           safety profile, as single agent or combined, are good candidates for maintenance&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives&#xD;
&#xD;
        -  The primary objective is to evaluate the benefit estimated by the PFS associated with&#xD;
           maintenance chemotherapy compared to observation in patients ≥ 60 years having achieved&#xD;
           a complete response after a high-dose MTX based induction chemotherapy&#xD;
&#xD;
        -  The secondary objectives are to assess:&#xD;
&#xD;
             -  Overall survival&#xD;
&#xD;
             -  Safety of maintenance chemotherapy&#xD;
&#xD;
             -  Neurocognitive outcome&#xD;
&#xD;
             -  Quality of life of the patients&#xD;
&#xD;
      Inclusion and exclusion criteria&#xD;
&#xD;
      At registration&#xD;
&#xD;
        -  Inclusion criteria&#xD;
&#xD;
             -  Newly diagnosed primary cerebral lymphoma&#xD;
&#xD;
             -  Age &gt;60 years&#xD;
&#xD;
             -  Pathology proven diagnosis&#xD;
&#xD;
             -  Positive cytology of the CSF or vitreous&#xD;
&#xD;
             -  Karnofsky Performance Status &gt;40&#xD;
&#xD;
             -  No evidence of systemic NHL (body CT scan, bone marrow biopsy)&#xD;
&#xD;
             -  Adequate haematological, renal and hepatic function&#xD;
&#xD;
             -  Calculated creatinine clearance &gt; 40 ml/min&#xD;
&#xD;
        -  Non inclusion criteria&#xD;
&#xD;
             -  Positive HIV serology&#xD;
&#xD;
             -  Preexisting immunodeficiency (organ transplant recipient)&#xD;
&#xD;
             -  Prior treatment for PCNSL&#xD;
&#xD;
             -  Isolated primary intra-ocular lymphoma&#xD;
&#xD;
             -  Low grade lymphoma&#xD;
&#xD;
             -  Any other active primary malignancy&#xD;
&#xD;
      At randomization&#xD;
&#xD;
        -  Complete response on MRI after induction chemotherapy according to the IPCG criteria&#xD;
&#xD;
        -  Karnofsky Performance Status &gt;40&#xD;
&#xD;
        -  Adequate haematological, renal and hepatic function&#xD;
&#xD;
      Study Design&#xD;
&#xD;
        -  This study is an open label multicenter randomized phase III trial comparing maintenance&#xD;
           chemotherapy versus observation in complete responders to high dose MTX based induction&#xD;
           chemotherapy.&#xD;
&#xD;
        -  Patients are registered to participate in the study at time of initial diagnosis and&#xD;
           study enrolment before the induction chemotherapy.&#xD;
&#xD;
        -  Induction chemotherapy (R-MPVA protocol) includes 4 to 5 monthly cycles of high dose MTX&#xD;
           (3.5g/m2, D1 and D15), procarbazine, vincristine, rituximab followed by one cycle of&#xD;
           high dose cytarabine consolidation.&#xD;
&#xD;
        -  Randomization to observation (arm 1) or maintenance (arm 2) will be carried out only for&#xD;
           patients in complete response (CR) after induction chemotherapy Arm 1: Observation Arm&#xD;
           2: Seven monthly R-MT cycles including high dose MTX (3.5g/m2, D1), TMZ, rituximab&#xD;
&#xD;
      Sample size, duration of the study, feasibility&#xD;
&#xD;
        -  295 patients need to be enrolled to randomize 192 patients&#xD;
&#xD;
        -  Duration of the study: 6 years (accrual period= 4 years; minimal follow-up = 2 years)&#xD;
&#xD;
           26 participating expert centers from the national LOC network&#xD;
&#xD;
      The trial is supported by the neurooncology ANOCEF and the lymphoma LYSA clinical research&#xD;
      groups.&#xD;
&#xD;
      Ancillary study LOCALYSE:&#xD;
&#xD;
      Role of [18F]-FDG brain PET in newly diagnosed primary cerebral lymphoma, in immunocompetent&#xD;
      patient older than 60 years&#xD;
&#xD;
      Rationale Patients older than 60 years account for half of cases of PCNSL and have a poorer&#xD;
      outcome. No prognostic or predictive factors exist for survival after initial remission.&#xD;
      [18F]FDG-PET (Fluoro Deoxy Glucose) plays a key role in grading and therapy monitoring of&#xD;
      systemic diffuse large B-cell type.&#xD;
&#xD;
      LOCALYZE is an ancillary PET/MR clinical study from BLOCAGE 01. The aim is to evaluate the&#xD;
      usefulness of [18F]FDG-PET to monitor treatment response in PCNSL (Primary Central Nervous&#xD;
      System Lymphoma) older than 60 years (n=56), in complement to multiparametric MRI.&#xD;
&#xD;
      Hypothesis We assume that the development of new imaging biomarker extracted from PET imaging&#xD;
      and multiparametric MRI, could improve the assessment of treatment response in PCNSL.&#xD;
&#xD;
      Primary aim To evaluate the predictive value of [18F]FDG-PET assessment performed at the&#xD;
      end-of-treatment (high-dose methotrexate based polychemotherapy), on progression free&#xD;
      survival in newly diagnosed PCNSL with age ≥60 years (n=56).&#xD;
&#xD;
      Primary Outcome Measures:&#xD;
&#xD;
      Progression free survival calculated from the date of completion of the end of chemotherapy&#xD;
      PET&#xD;
&#xD;
      Study design&#xD;
&#xD;
      Three [18F]-FDG PET/MR will be performed in the Department of Nuclear Medicine -&#xD;
      Pitié-Salpêtrière Hospital:&#xD;
&#xD;
        -  prior to initiation of R-MPVA chemotherapy (Rituximab Methotrexate Procarbazine&#xD;
           Vincristine Aracytine ) (PET#1),&#xD;
&#xD;
        -  after two chemotherapy cycles (PET#2),&#xD;
&#xD;
        -  at the end of the first-line chemotherapy regimens (PET#3).&#xD;
&#xD;
      Inclusion criteria (=Blocage-01) Blocage01 eligibility&#xD;
&#xD;
      Exclusion criteria&#xD;
&#xD;
        -  Uncontrolled diabetes with fasting glycaemia &gt; 200 mg/dL&#xD;
&#xD;
        -  Sensitivity to active substance in [18F]-FDG&#xD;
&#xD;
        -  Calculated creatinine clearance &lt; 40 ml/min&#xD;
&#xD;
        -  No contraindication to MRI&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity graded according to the NCI-CTCAE</measure>
    <time_frame>6 years</time_frame>
    <description>Toxicity graded according to the NCI-CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive functions evaluated by a standardized and validated test battery exploring 5 cognitive domains</measure>
    <time_frame>6 years</time_frame>
    <description>Cognitive functions evaluated by a standardized and validated test battery exploring 5 cognitive domains</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 years</time_frame>
    <description>Quality of life assessed by the EORTC QLC-C30 questionnaire and the brain cancer module (BCM20)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">295</enrollment>
  <condition>Primary Central Nervous System Lymphoma</condition>
  <arm_group>
    <arm_group_label>maintenance chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clinical examination and MRI will be performed every 3 months for 2 years and then every 6 months until tumor progression.&#xD;
Neurocognitive tests will be performed at randomization and annually. Quality of life questionnaires at randomisation and every 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Clinical examination and MRI will be performed every 3 months for 2 years and then every 6 months until tumor progression.&#xD;
Neurocognitive tests will be performed at randomization and annually. Quality of life questionnaires at randomisation and every 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab, Methotrexate, Temozolomide</intervention_name>
    <description>Seven monthly R-MT cycles including high dose MTX (3.5g/m2, D1), TMZ, rituximab.</description>
    <arm_group_label>maintenance chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria At registration Inclusion criteria&#xD;
&#xD;
          -  newly diagnosed primary cerebral lymphoma&#xD;
&#xD;
          -  Age ≥60 years&#xD;
&#xD;
          -  Pathology proven diagnosis or positive cytology of the CSF or vitreous&#xD;
&#xD;
          -  Karnofsky Performance Status ≥40&#xD;
&#xD;
          -  No evidence of systemic NHL (body CT scan, bone marrow biopsy)&#xD;
&#xD;
          -  Adequate haematological, renal and hepatic function&#xD;
&#xD;
          -  Calculated creatinine clearance &gt; 40 ml/min&#xD;
&#xD;
        At randomization&#xD;
&#xD;
          -  Complete response on MRI after induction chemotherapy according to the IPCG criteria&#xD;
&#xD;
          -  Karnofsky Performance Status ≥40&#xD;
&#xD;
          -  Adequate haematological, renal and hepatic function&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Positive HIV serology&#xD;
&#xD;
          -  Preexisting immunodeficiency (organ transplant recipient)&#xD;
&#xD;
          -  Prior treatment for PCNSL&#xD;
&#xD;
          -  Isolated primary intra-ocular lymphoma&#xD;
&#xD;
          -  Low grade lymphoma&#xD;
&#xD;
          -  Any other active primary malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khe HOANG-XUAN, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Khe HOANG-XUAN, MD, PhD</last_name>
    <phone>+33 - 1.42.16.03.81</phone>
    <email>khe.hoang-xuan@psl.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khe HOANG-XUAN, MD, PhD</last_name>
      <phone>+33 - 1.42.16.03.81</phone>
      <email>khe.hoang-xuan@psl.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>December 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2014</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

